UpdatesPress Release
Cipla secured an exclusive licensing agreement with SBP Group for TQB2102, a promising HER2 bispecific ADC.
Cipla LimitedCIPLA · Filed with the exchange
This boosts Cipla's oncology pipeline for breast cancer patients across India, South Africa, and key emerging markets, enhancing access to innovative therapies.
No comments yet. Be the first.